Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Development strategy for new cancer drugs going global (CHN、USA、AUS)
-
USTC / China-Japan Pharmaceutical & New Materials Innovation Special Session
Stay tuned
Session Planner: Yonghan Hu, Deputy General Manager & CTO, Evopoint Bio
13:00–13:05 Opening Remarks
Jingyu Li,Founder & CEO,Cellatopia
Part I: Antibody & Small Molecule New Drug R&D
13:05-13:25 Insights from the Development of GIPR/GLP-1R Bispecific Molecule AMG133: Mechanisms, Applications, and Case Studies of Peptide-Drug Conjugates
Junmin Ye, CSO, Salubris
13:25-13:45 Nanobody Drug Development: Strategies, Case Studies, and Trends
Tengchuan Jin, Professor, USTC Life Sciences and Medicine ; Investigator, State Key Laboratory of Immune Response and Immunotherapy
13:45-14:05 mRNA-Encoded Antibodies: Targeted Delivery Ushers in a New Era of Precision Immunotherapy
Congcong Xu, Professor, College of Pharmaceutical Sciences, Soochow University
14:05-14:25 Developing Bifunctional PROTACs to Address Undruggable Targets
Shaoyun Xiang, Founder & CEO, Polymed
14:25-14:45 Remodeling CNS Drug Discovery: A Transformative Era of Central Nervous System Drug R&D
Xuechu Zhen, Professor, College of Pharmaceutical Sciences, Soochow University
14:45-15:05 Coffee Break
Part II: New Drug Services (Technology Platforms, CDMO, Legal, etc.)
15:05-15:25 AI-Driven Cell Therapy and Regenerative Medicine: Current Status, Challenges, and Future Pathways
Jingyu Li,Founder & CEO,Cellatopia
15:25-15:45 Opportunities and Challenges of Domestic Substitution in Biopharma
Zhi Li, CEO, Intellective Bio
15:45-16:05 3D Micro-tissue Technology: Bridging In Vivo and In Vitro, Reshaping Preclinical Drug Development
Hongda Sheng, Vice President, Hepobio
16:05-16:25 From Project Initiation to Commercial Launch: A Full Landscape of U.S. Litigation Risks for Biopharmaceutical Enterprises
Yingli Wang, Partner, Perkins Coie LLP
16:25-17:05 Panel Discussion:USTC’s Original Innovation – Biopharmaceutical Innovation and Industry-Academia-Research Translation in the AI Era
Haiyang Wei (Moderator), Vice President,Evopoint Bio
Shaoyun Xiang, Founder & CEO, Polymed
Yonghan Hu, Deputy General Manager & CTO, Evopoint Bio
Junmin Ye, CSO, Salubris
Yingli Wang, Partner, Perkins Coie LLP
Tengchuan Jin, Professor, USTC Life Sciences and Medicine ; Investigator, State Key Laboratory of Immune Response and Immunotherapy
Rongkuan Hu, CEO,Starna
17:05-17:10 Summary & Closing
Jingyu Li,Founder & CEO,Cellatopia